2354-2355 / 2953
Prostate cancer-specific mortality in
RCTs for dose escalation
Trial
No.
Follow-up High risk
PCa deaths
PROG
1
393
9 yr
5%
4 (1%)
MDA
2
305
9 yr
33%
10 (3%)
RT01
3
843
5 yr
44%
36 (4%)
NKI
4
669
5.8 yr
55%
87 (13%)
RT01
5
843
10 yr
44%
91 (11%)
ICR/RMH
6
126
14 yr
59%
19 (15%)
1
. Zietman AL, et al. J Clin Oncol 2010;28:1106–11; 2. Kuban DA, et al. Int J Radiat Oncol Biol Phys 2011;79:1310–7; 3.
Dearnaley DP, et al. Lancet Oncol 2007;8:475–87; 4. Peeters ST, et al. J Clin Oncol 2006;24:1990–6; 5.Dearnaley DP et al.
ECCO/ESMO Sept 2011. Abstract 21LBA; 6. Creak AL, et al. ESTRO May 2011
RCT; randomized clinical trial
17